M
Mark E. Cooper
Researcher at University of Queensland
Publications - 1514
Citations - 141899
Mark E. Cooper is an academic researcher from University of Queensland. The author has contributed to research in topics: Diabetes mellitus & Diabetic nephropathy. The author has an hindex of 158, co-authored 1463 publications receiving 124887 citations. Previous affiliations of Mark E. Cooper include University of Cambridge & University of Adelaide.
Papers
More filters
Journal ArticleDOI
Reduced bone mass in daughters of women with osteoporosis
Ego Seeman,John L. Hopper,Leon A. Bach,Mark E. Cooper,Elizabeth Parkinson,J. McKay,George Jerums +6 more
TL;DR: It is concluded that daughters of women with osteoporosis have reduced bone mass in the lumbar spine and perhaps in the femoral neck; this reduction in bone mass may put them at increased risk for fractures.
Journal ArticleDOI
Aminoglycoside Antibiotics in the 21st Century
Bernd Becker,Mark E. Cooper +1 more
TL;DR: It is time to have a fresh look at this old class of aminoglycoside antibiotics to reinvigorate the struggle against multidrug-resistant pathogens.
Journal ArticleDOI
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) trial
Wouter B.A. Eijkelkamp,Zhongxin Zhang,Giuseppe Remuzzi,Hans-Henrik Parving,Hans-Henrik Parving,Mark E. Cooper,William F. Keane,Shahnaz Shahinfar,Gilbert W. Gleim,Matthew R. Weir,Barry M. Brenner,Dick de Zeeuw +11 more
TL;DR: Antihypertensive treatment that is aimed at improving renal outcomes in patients with diabetic nephropathy may require a dual strategy, targeting both SBP and albuminuria reduction, according to a study investigated the adequacy of this approach in 1428 patients from the placebo-controlled Reduction of Endpoints in NIDDM.
Journal ArticleDOI
Reduction of the Accumulation of Advanced Glycation End Products by ACE Inhibition in Experimental Diabetic Nephropathy
Josephine M. Forbes,Josephine M. Forbes,Mark E. Cooper,Vicki Thallas,Wendy C. Burns,Merlin C. Thomas,Gail C Brammar,Fiona T.H. Lee,Sharon L. Grant,Louise M Burrell,George Jerums,Tanya M. Osicka +11 more
TL;DR: A relationship between the renin-angiotensin system and the accumulation of AGEs in experimental diabetic nephropathy that may be linked through oxidative stress is identified.
Journal ArticleDOI
Role for NLRP3 Inflammasome-mediated, IL-1β-Dependent Responses in Severe, Steroid-Resistant Asthma.
Richard Kim,James W. Pinkerton,Ama Tawiah Essilfie,Avril A. B. Robertson,Katherine J. Baines,Alexandra C. Brown,Jemma R. Mayall,M Khadem Ali,Malcolm R. Starkey,Nicole G. Hansbro,Jeremy A. Hirota,Lisa Wood,Jodie L. Simpson,Darryl A. Knight,Peter A. B. Wark,Peter G. Gibson,Luke A. J. O'Neill,Mark E. Cooper,Jay C. Horvat,Philip M. Hansbro +19 more
TL;DR: Investigation of mouse models of Chlamydia and Haemophilus respiratory infection‐mediated, ovalbumin‐induced severe, steroid‐resistant allergic airway disease found NLRP3 inflammasome responses drive experimental severe, steroids‐resistant asthma and are potential therapeutic targets in this disease.